Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seretide Evohaler versus generic salmeterol + fluticasone HFA pMDI in asthma using functional respiratory imaging
2012-005789-36Phase 3Completed
- Sponsor
- FLUIDDA
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salmeterol + fluticasone, salmeterol and fluticasone propionate in asthma (2 arms), sponsored by FLUIDDA. Primary endpoint: Functional respiratory imaging and computational fluid dynamics parameters. Started Jan 2013; status: completed.
02
Drugs
salmeterol + fluticasonesalmeterolfluticasone propionate
03
Conditions
asthma
Beyond the preview
Go deeper on 2012-005789-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005789-36.